According to UK-based Nemaura, those suffering from acute arthritis or other musculoskeletal maladies and using typical OTC gels or lotions to ease related pain from inflammation, will be interested in the results of recent laboratory trials demonstrating the safety and efficacy of two new gels—products the company says can achieve penetration rates three times faster than similar, currently available formulations.
As the company pointed out, approximately 10 million people are living with arthritis in the UK alone. The two new gels administer non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and can last up to 48 hours.
Developed over the course of the last 18 months, Nemaura has tested its proprietary Memspatch® delivery systems with common NSAIDs. Nemaura explained that orally and parenterally administered NSAIDs have undesirable pharmocokinetic attributes, whereas skin-based delivery systems may be considered more attractive. The company noted, however, that with age, skin tends to thicken which often diminishes the effectiveness of topically applied therapeutics. However, Nemaura has said that its transdermal gel formula is expected to overcome these limitations as it provides for either rapid or controlled delivery of drug formulations.
Nemaura CEO Dr. Faz Chowdhury explained, “Our goal is to improve the life experience of anyone affected by pain. We are excited by our progress, as these results bring a new product closer to market. In the past six months we have grown our team of device technologists, chemists and scientists to 35, and plan for further expansion in 2018 on the back of these promising results."
Dr. Faz Chowdury
.svg)
